Search





Search





Markets
/
Stocks
/
nasdaq-mirm
/

Mirum Pharmaceuticals Inc

MIRM

Add to Watchlist

112.855USD

+5.975+5.59%

Market hours （ET）Quotes delayed by 15 min

5.86BMarket Cap

LossP/E TTM



Mirum Pharmaceuticals Inc

112.855

+5.975+5.59%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Mirum Pharmaceuticals Inc

Currency: USD Updated: 2026-05-12

Key Insights

Mirum Pharmaceuticals Inc's fundamentals are relatively very healthy, with industry-average ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 11 out of 156 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 146.36.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Mirum Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

11 / 156

Overall Ranking

41 / 4490

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Mirum Pharmaceuticals Inc Highlights

StrengthsRisks

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 179.71% year-on-year.

Fairly Valued

The company’s latest PE is -7.86, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 68.01M shares, increasing 6.60% quarter-over-quarter.

Held by Ken Fisher

Star Investor Ken Fisher holds 93.11K shares of this stock.

Analyst Rating

Based on 11 analysts

Buy

Current Rating

146.364

Target Price

+36.58%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-12

The current financial score of Mirum Pharmaceuticals Inc is 8.10, ranking 72 out of 156 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 159.88M, representing a year-over-year increase of 43.28%, while its net profit experienced a year-over-year increase of 5283.63%.

Score

Industry at a Glance

Previous score

8.10

Change



Financials

8.30

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

5.95

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.82

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.45

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Mirum Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-05-12

The current valuation score of Mirum Pharmaceuticals Inc is 7.28, ranking 82 out of 156 in the Pharmaceuticals industry. Its current P/E ratio is -7.86, which is -39.13% below the recent high of -4.79 and -2907.78% above the recent low of -236.52.

Score

Industry at a Glance

Previous score

7.28

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 11/156

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-12

The current earnings forecast score of Mirum Pharmaceuticals Inc is 8.73, ranking 11 out of 156 in the Pharmaceuticals industry. The average price target is 91.00, with a high of 95.00 and a low of 80.00.

Score

Industry at a Glance

Previous score

8.73

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 11 analysts

Buy

Current Rating

146.364

Target Price

+36.58%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

Mirum Pharmaceuticals Inc

MIRM

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

Vertex Pharmaceuticals Inc

VRTX

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-12

The current price momentum score of Mirum Pharmaceuticals Inc is 9.42, ranking 15 out of 156 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 116.47 and the support level at 92.81, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.33

Change

0.09

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

2.102

Buy

RSI(14)

62.306

Neutral

STOCH(KDJ)(9,3,3)

77.290

Neutral

ATR(14)

6.029

High Vlolatility

CCI(14)

68.950

Neutral

Williams %R

21.636

Buy

TRIX(12,20)

0.490

Sell

StochRSI(14)

25.411

Neutral

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

106.644

Buy

MA10

103.286

Buy

MA20

98.817

Buy

MA50

94.691

Buy

MA100

93.571

Buy

MA200

81.558

Buy

Institutional Confidence

Currency: USD Updated: 2026-05-12

The current institutional shareholding score of Mirum Pharmaceuticals Inc is 10.00, ranking 1 out of 156 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 111.53%, representing a quarter-over-quarter decrease of 3.46%. The largest institutional shareholder is PRFDX, holding a total of 1.38M shares, representing 2.26% of shares outstanding, with 19.02% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Frazier Life Sciences Management, L.P.

7.68M

+13.02%

Janus Henderson Investors

6.07M

+21.36%

BlackRock Institutional Trust Company, N.A.

3.13M

+3.21%

State Street Investment Management (US)

2.14M

+59.18%

Eventide Asset Management, LLC

2.09M

-17.01%

BVF Partners L.P.

1.50M

T. Rowe Price Associates, Inc.

Star Investors

1.38M

+10.69%

Novo Holdings A/S

1.26M

Risk Assessment

Currency: USD Updated: 2026-05-12

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Mirum Pharmaceuticals Inc is 6.60, ranking 52 out of 156 in the Pharmaceuticals industry. The company's beta value is 0.52. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Mirum Pharmaceuticals Inc’s latest ESG disclosure is at an average level in the Pharmaceuticals industry, showing no material impact on overall risk.